Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can eczema patients safely take less dupilumab? new trial aims to find out

NCT ID NCT05642208

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether people with atopic dermatitis (eczema) that has been well-controlled for at least six months can safely take dupilumab less often. About 256 teens and adults will either stick with their usual every-two-week injection or gradually space out doses. The goal is to see if the step-down approach keeps the disease under control just as well over one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dupilumab
What this could lead to
If successful, this could show that patients with well-controlled atopic dermatitis can safely take dupilumab less often while still keeping symptoms under control.
What could go wrong
This is a Phase 4 trial, so dupilumab is already approved. The main question is whether reducing the dose will cause a flare-up in some patients. Results may not apply to those with more severe or uncontrolled disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 256 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 12 years * Moderate to severe AD treated with dupilumab every 2 weeks * Written informed consent (patient and/or person who has parental authority) * Dupilumab treatment for at least one year * Controlled AD (ADCT\<7 and IGA ≤ 2) and assessed as controlled by the investigator since at least 6 months without tapering dosage of dupilumab * Amount of topical treatment (TCS or calcineurin inhibitor) stable for 6 months and less than 60 g/month Exclusion Criteria: * Patients with Side effects of dupilumab * Non controlled AD: ADCT ≥ 7 or IGA ≥ 3 * Female patient must not be pregnant\*, breastfeeding or considering becoming pregnant * Patient under judicial protection * Adults under guardianship or trusteeship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Eczema, atopic

Contacts and locations

Locations

  • Amiens University hospital

    Amiens, France

  • CH de Le Mans

    Le Mans, France

  • CH de Niort

    Niort, France

  • CH de Saint Nazaire

    Saint-Nazaire, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHRU de Brest

    Brest, France

  • CHRU de Lille

    Lille, France

  • CHRU de Tours

    Tours, France

  • CHU d'Angers

    Angers, France

  • CHU de Besançon

    Besançon, France

  • CHU de Bordeaux Adulte

    Bordeaux, France

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • CHU de Dijon

    Dijon, France

  • CHU de Grenoble

    Grenoble, France

  • CHU de La Réunion

    Saint-Pierre, La Réunion, Reunion

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nantes

    Nantes, France

  • CHU de Poitiers

    Poitiers, France

  • CHU de Reims

    Reims, France

  • CHU de Rennes

    Rennes, France

  • CHU de Rouen

    Rouen, France

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, France

  • GH La Rochelle - Ré-Aunis

    La Rochelle, France

  • Groupement des Hôpitaux de l'institut Catholique de Lille

    Lille, France

  • HIA Sainte Anne

    Toulon, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Necker-Enfants malades

    Paris, France

  • Hôpital Saint Louis

    Paris, France

  • Hôpital Tenon

    Paris, France

  • Hôpital Victor Dupouy

    Argenteuil, France

  • Hôpital de la Timone

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.